Neuroendocrine Carcinoma Drugs Market Acquire Huge Growth, Global Opportunities and Trends to 2027 – KSU ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
7 January 2021
OKYO Pharma Limited ( OKYO or the Company ) today announces that Gabriele Cerrone has been appointed as a non-executive chairman of the company and Dr Gary S. Jacob has been appointed as Chief Executive Officer and director of the company, both with immediate effect. Gabriele Cerrone (age: 48) Mr Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies. He has founded ten biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken seven of these companies to the NASDAQ Market and two to the Main Market and AIM Market in London. Mr Cerrone is Executive Chairman of dual listed Tiziana Life Sciences plc. Mr Cerrone co-founded Cardiff Oncology, Inc. (NASDAQ: CRDF), an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) and Callisto Pharmaceutical